Alzheimer’s Disease 2024: The Role of Biomarkers

August 14, 2024
11 a.m.–Noon CT


Free for all participants.


The field of Alzheimer’s disease is evolving rapidly, and laboratory testing is now playing a major role in diagnosis and treatment decisions. Early, accurate diagnosis is important to access FDA-approved medications and improve patient care, but the plethora of lab test options can be confusing. Blood and cerebrospinal fluid (CSF) options exist that have shown high concordance with amyloid positron emission tomography (PET) scans, but careful consideration should be put into ordering the right test for the right patient.

This webinar, with expert presenters who have both extensive lab and clinical experience, will discuss the latest updates in Alzheimer’s disease diagnostic criteria as well as a comprehensive review of the laboratory testing landscape to help listeners better understand their options. 


Ronald Petersen, M.D., Ph.D.
Professor of Neurology
Chester and Debbie Cadieux Director, Mayo Clinic Alzheimer's Disease Research Center
Cora Kanow Professor of Alzheimer's Disease Research
Mayo Clinic
Rochester, Minnesota 

Alicia Algeciras-Schimnich

Alicia Algeciras-Schimnich, Ph.D.
Professor of Laboratory Medicine and Pathology
Division of Clinical Biochemistry
Mayo Clinic
Rochester, Minnesota 

Learning objectives

Upon completion of this activity, participants should be able to:

  • List the updated criteria for diagnosing Alzheimer’s disease.
  • Discuss the role of fluid biomarkers (both blood and CSF) for diagnosing Alzheimer’s disease.
  • Identify the limitations of fluid biomarkers (both blood and CSF) for Alzheimer’s disease.
  • Recognize the importance of performance measures when evaluating fluid biomarkers for Alzheimer’s disease.

Intended audience

This webinar is appropriate for any provider who sees patients with Alzheimer’s disease, neurologists, primary care internal medicine, family medicine, nurse practitioners, physician assistants, laboratory directors, lab supervisors, pathologists, and laboratory send-out coordinators/managers.


The following types of credit are offered for this event:


Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.

State of Florida

Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the Clinical Laboratory Sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for General credit. This program has been approved for 1.0 contact hour.

To obtain credit

1. Register for and participate in the program.

2. Complete the evaluation that will be sent to you after the program.

3. Generate and print your certificate(s).

Level of instruction for this program is intermediate.

Faculty disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.


Contact us:

MCL Education

This post was developed by our Education and Technical Publications Team.